{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:52:09Z","timestamp":1787003529086,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1817582"],"award-info":[{"award-number":["1817582"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1817582"],"award-info":[{"award-number":["1817582"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1817582"],"award-info":[{"award-number":["1817582"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transcriptional addiction is recognized as a valid therapeutic target in cancer, whereby the dependency of cancer cells on oncogenic transcriptional regulators may be pharmacologically exploited. However, a comprehensive understanding of the key factors within the transcriptional machinery that might afford a useful therapeutic window remains elusive. Herein, we present a cross-omics investigation into the functional specialization of the transcriptional cyclin dependent kinases (tCDKs) through analysis of high-content genetic dependency, gene expression, patient survival, and drug response datasets. This analysis revealed specialization among tCDKs in terms of contributions to cancer cell fitness, clinical prognosis, and interaction with oncogenic signaling pathways. CDK7 and CDK9 stand out as the most relevant targets, albeit through distinct mechanisms of oncogenicity and context-dependent contributions to cancer survival and drug sensitivity. Genetic ablation of CDK9, but not CDK7, mimics the effect on cell viability the loss of key components of the transcriptional machinery. Pathway analysis of genetic co-dependency and drug sensitivity data show CDK7 and CDK9 have distinct relationships with major oncogenic signatures, including MYC and E2F targets, oxidative phosphorylation, and the unfolded protein response. Altogether, these results inform the improved design of therapeutic strategies targeting tCDKs in cancer.<\/jats:p>","DOI":"10.1038\/s41598-022-26860-1","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T16:03:04Z","timestamp":1672243384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multi-omics investigation reveals functional specialization of transcriptional cyclin dependent kinases in cancer biology"],"prefix":"10.1038","volume":"12","author":[{"given":"Micah G.","family":"Donovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galbraith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin M.","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"26860_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell 168, 629\u2013643. https:\/\/doi.org\/10.1016\/j.cell.2016.12.013 (2017).","journal-title":"Cell"},{"key":"26860_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cell.2015.09.013","volume":"163","author":"HL Franco","year":"2015","unstructured":"Franco, H. L. & Kraus, W. L. No driver behind the wheel? Targeting transcription in cancer. Cell 163, 28\u201330. https:\/\/doi.org\/10.1016\/j.cell.2015.09.013 (2015).","journal-title":"Cell"},{"key":"26860_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/21541264.2018.1539615","volume":"10","author":"MD Galbraith","year":"2019","unstructured":"Galbraith, M. D., Bender, H. & Espinosa, J. M. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription 10, 118\u2013136. https:\/\/doi.org\/10.1080\/21541264.2018.1539615 (2019).","journal-title":"Transcription"},{"key":"26860_CR4","first-page":"1913","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. CDK inhibitors in cancer therapy, an overview of recent development. Am. J. Cancer Res. 11, 1913\u20131935 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"26860_CR5","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1038\/s41388-022-02347-1","volume":"41","author":"TA Constantin","year":"2022","unstructured":"Constantin, T. A., Greenland, K. K., Varela-Carver, A. & Bevan, C. L. Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene 41, 3303\u20133315. https:\/\/doi.org\/10.1038\/s41388-022-02347-1 (2022).","journal-title":"Oncogene"},{"key":"26860_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","volume":"22","author":"SJ Vervoort","year":"2022","unstructured":"Vervoort, S. J. et al. Targeting transcription cycles in cancer. Nat. Rev. Cancer 22, 5\u201324. https:\/\/doi.org\/10.1038\/s41568-021-00411-8 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"26860_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/21541264.2016.1268244","volume":"8","author":"RP Fisher","year":"2017","unstructured":"Fisher, R. P. CDK regulation of transcription by RNAP II: Not over \u2019til it\u2019s over?. Transcription 8, 81\u201390. https:\/\/doi.org\/10.1080\/21541264.2016.1268244 (2017).","journal-title":"Transcription"},{"key":"26860_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.Cd-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y. & Ashworth, A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 10, 351\u2013370. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-0528 (2020).","journal-title":"Cancer Discov."},{"key":"26860_CR9","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1101\/gad.1477006","volume":"20","author":"HP Phatnani","year":"2006","unstructured":"Phatnani, H. P. & Greenleaf, A. L. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 20, 2922 (2006).","journal-title":"Genes Dev."},{"key":"26860_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.molcel.2009.10.019","volume":"36","author":"S Buratowski","year":"2009","unstructured":"Buratowski, S. Progression through the RNA polymerase II CTD cycle. Mol. Cell 36, 541\u2013546. https:\/\/doi.org\/10.1016\/j.molcel.2009.10.019 (2009).","journal-title":"Mol. Cell"},{"key":"26860_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nsmb.3285","volume":"23","author":"J Zaborowska","year":"2016","unstructured":"Zaborowska, J., Egloff, S. & Murphy, S. The pol II CTD: New twists in the tail. Nat. Struct. Mol. Biol. 23, 771\u2013777. https:\/\/doi.org\/10.1038\/nsmb.3285 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"26860_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/21541264.2018.1556915","volume":"10","author":"CB Fant","year":"2019","unstructured":"Fant, C. B. & Taatjes, D. J. Regulatory functions of the Mediator kinases CDK8 and CDK19. Transcription 10, 76\u201390. https:\/\/doi.org\/10.1080\/21541264.2018.1556915 (2019).","journal-title":"Transcription"},{"key":"26860_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nsmb.2399","volume":"19","author":"S Larochelle","year":"2012","unstructured":"Larochelle, S. et al. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat. Struct. Mol. Biol. 19, 1108\u20131115. https:\/\/doi.org\/10.1038\/nsmb.2399 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"26860_CR14","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1101\/gad.341545.120","volume":"34","author":"JK Rimel","year":"2020","unstructured":"Rimel, J. K. et al. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription. Genes Dev. 34, 1452\u20131473. https:\/\/doi.org\/10.1101\/gad.341545.120 (2020).","journal-title":"Genes Dev."},{"key":"26860_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava, G. P., Fan, H., Coombes, R. C., Buluwela, L. & Ali, S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 39, 805\u2013823. https:\/\/doi.org\/10.1007\/s10555-020-09885-8 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"26860_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4161\/trns.1.1.12373","volume":"1","author":"MD Galbraith","year":"2010","unstructured":"Galbraith, M. D., Donner, A. J. & Espinosa, J. M. CDK8: A positive regulator of transcription. Transcription 1, 4\u201312. https:\/\/doi.org\/10.4161\/trns.1.1.12373 (2010).","journal-title":"Transcription"},{"key":"26860_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature14904","volume":"526","author":"HE Pelish","year":"2015","unstructured":"Pelish, H. E. et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 526, 273\u2013276. https:\/\/doi.org\/10.1038\/nature14904 (2015).","journal-title":"Nature"},{"key":"26860_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nsmb.1752","volume":"17","author":"AJ Donner","year":"2010","unstructured":"Donner, A. J., Ebmeier, C. C., Taatjes, D. J. & Espinosa, J. M. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat. Struct. Mol. Biol. 17, 194\u2013201. https:\/\/doi.org\/10.1038\/nsmb.1752 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"26860_CR19","doi-asserted-by":"publisher","first-page":"12558","DOI":"10.18632\/oncotarget.14894","volume":"8","author":"MS McDermott","year":"2017","unstructured":"McDermott, M. S. et al. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget 8, 12558\u201312575. https:\/\/doi.org\/10.18632\/oncotarget.14894 (2017).","journal-title":"Oncotarget"},{"key":"26860_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.biochi.2013.10.004","volume":"97","author":"J Nemet","year":"2014","unstructured":"Nemet, J., Jelicic, B., Rubelj, I. & Sopta, M. The two faces of Cdk8, a positive\/negative regulator of transcription. Biochimie 97, 22\u201327. https:\/\/doi.org\/10.1016\/j.biochi.2013.10.004 (2014).","journal-title":"Biochimie"},{"key":"26860_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1101\/gad.12.3.370","volume":"12","author":"S Larochelle","year":"1998","unstructured":"Larochelle, S., Pandur, J., Fisher, R. P., Salz, H. K. & Suter, B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev 12, 370\u2013381. https:\/\/doi.org\/10.1101\/gad.12.3.370 (1998).","journal-title":"Genes Dev"},{"key":"26860_CR22","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1242\/jcs.02718","volume":"118","author":"RP Fisher","year":"2005","unstructured":"Fisher, R. P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J. Cell Sci. 118, 5171\u20135180. https:\/\/doi.org\/10.1242\/jcs.02718 (2005).","journal-title":"J. Cell Sci."},{"key":"26860_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nsmb1028","volume":"13","author":"S Larochelle","year":"2006","unstructured":"Larochelle, S. et al. Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat. Struct. Mol. Biol. 13, 55\u201362. https:\/\/doi.org\/10.1038\/nsmb1028 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"26860_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.molcel.2007.02.003","volume":"25","author":"S Larochelle","year":"2007","unstructured":"Larochelle, S. et al. Requirements for Cdk7 in the assembly of Cdk1\/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol. Cell 25, 839\u2013850 (2007).","journal-title":"Mol. Cell"},{"key":"26860_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.molcel.2013.04.003","volume":"50","author":"MM Schachter","year":"2013","unstructured":"Schachter, M. M. et al. A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. Mol. Cell 50, 250\u2013260. https:\/\/doi.org\/10.1016\/j.molcel.2013.04.003 (2013).","journal-title":"Mol. Cell"},{"key":"26860_CR26","doi-asserted-by":"publisher","first-page":"109013","DOI":"10.1016\/j.celrep.2021.109013","volume":"35","author":"B Veo","year":"2021","unstructured":"Veo, B. et al. Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. Cell Rep. 35, 109013. https:\/\/doi.org\/10.1016\/j.celrep.2021.109013 (2021).","journal-title":"Cell Rep."},{"key":"26860_CR27","doi-asserted-by":"publisher","first-page":"126637","DOI":"10.1016\/j.bmcl.2019.126637","volume":"29","author":"C S\u00e1nchez-Mart\u00ednez","year":"2019","unstructured":"S\u00e1nchez-Mart\u00ednez, C., Lallena, M. J., Sanfeliciano, S. G. & de Dios, A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015\u20132019). Bioorg. & Med. Chem. Lett. 29, 126637. https:\/\/doi.org\/10.1016\/j.bmcl.2019.126637 (2019).","journal-title":"Bioorg. & Med. Chem. Lett."},{"key":"26860_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski, R. Jr. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol. Res. 139, 471\u2013488. https:\/\/doi.org\/10.1016\/j.phrs.2018.11.035 (2019).","journal-title":"Pharmacol. Res."},{"key":"26860_CR29","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/acs.jmedchem.1c01171","volume":"65","author":"JJ Marineau","year":"2022","unstructured":"Marineau, J. J. et al. Discovery of SY-5609: A selective, noncovalent inhibitor of CDK7. J. Med. Chem. 65, 1458\u20131480. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01171 (2022).","journal-title":"J. Med. Chem."},{"key":"26860_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","volume":"26","author":"CL Christensen","year":"2014","unstructured":"Christensen, C. L. et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26, 909\u2013922. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.019 (2014).","journal-title":"Cancer Cell"},{"key":"26860_CR31","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/1078-0432.Ccr-18-3788","volume":"25","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 25, 6195\u20136205. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3788 (2019).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"26860_CR32","first-page":"3664","volume":"10","author":"JR Huang","year":"2018","unstructured":"Huang, J. R. et al. Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo. Am. J. Transl. Res. 10, 3664\u20133676 (2018).","journal-title":"Am. J. Transl. Res."},{"key":"26860_CR33","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1158\/1078-0432.Ccr-19-1418","volume":"26","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Targeting super-enhancer-associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 26, 2681\u20132692. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1418 (2020).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"26860_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.Ccr-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado, J. et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 26, 922\u2013934. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1853 (2020).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"26860_CR35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.bbrc.2019.10.052","volume":"520","author":"M Geng","year":"2019","unstructured":"Geng, M. et al. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma. Biochem. Biophys. Res. Commun. 520, 544\u2013550. https:\/\/doi.org\/10.1016\/j.bbrc.2019.10.052 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"26860_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","volume":"33","author":"AB Iniguez","year":"2018","unstructured":"Iniguez, A. B. et al. EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell 33, 202-216 e206. https:\/\/doi.org\/10.1016\/j.ccell.2017.12.009 (2018).","journal-title":"Cancer Cell"},{"key":"26860_CR37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/gutjnl-2019-318506","volume":"69","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut 69, 727\u2013736. https:\/\/doi.org\/10.1136\/gutjnl-2019-318506 (2020).","journal-title":"Gut"},{"key":"26860_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ebiom.2017.11.013","volume":"26","author":"II Nitulescu","year":"2017","unstructured":"Nitulescu, I. I. et al. Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation. EBioMedicine 26, 112\u2013125. https:\/\/doi.org\/10.1016\/j.ebiom.2017.11.013 (2017).","journal-title":"EBioMedicine"},{"key":"26860_CR39","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","volume":"30","author":"M Malumbres","year":"2005","unstructured":"Malumbres, M. & Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30, 630\u2013641. https:\/\/doi.org\/10.1016\/j.tibs.2005.09.005 (2005).","journal-title":"Trends Biochem. Sci."},{"key":"26860_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2148-14-10","volume":"14","author":"L Cao","year":"2014","unstructured":"Cao, L. et al. Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages. BMC Evol. Biol. 14, 10. https:\/\/doi.org\/10.1186\/1471-2148-14-10 (2014).","journal-title":"BMC Evol. Biol."},{"key":"26860_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","volume":"22","author":"JM Dempster","year":"2021","unstructured":"Dempster, J. M. et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 22, 343. https:\/\/doi.org\/10.1186\/s13059-021-02540-7 (2021).","journal-title":"Genome Biol."},{"key":"26860_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400-416.e411. https:\/\/doi.org\/10.1016\/j.cell.2018.02.052 (2018).","journal-title":"Cell"},{"key":"26860_CR43","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57116","author":"K Shimada","year":"2021","unstructured":"Shimada, K., Bachman, J. A., Muhlich, J. L. & Mitchison, T. J. shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data. Elife https:\/\/doi.org\/10.7554\/eLife.57116 (2021).","journal-title":"Elife"},{"key":"26860_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.molcel.2016.09.002","volume":"64","author":"C Jeronimo","year":"2016","unstructured":"Jeronimo, C. et al. Tail and kinase modules differently regulate core mediator recruitment and function in vivo. Mol. Cell 64, 455\u2013466. https:\/\/doi.org\/10.1016\/j.molcel.2016.09.002 (2016).","journal-title":"Mol. Cell"},{"key":"26860_CR45","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1016\/j.molcel.2022.09.016","volume":"82","author":"L Warfield","year":"2022","unstructured":"Warfield, L., Donczew, R., Mahendrawada, L. & Hahn, S. Yeast Mediator facilitates transcription initiation at most promoters via a Tail-independent mechanism. Mol. Cell 82, 4033-4048.e4037. https:\/\/doi.org\/10.1016\/j.molcel.2022.09.016 (2022).","journal-title":"Mol. Cell"},{"key":"26860_CR46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.39633","author":"ER Knoll","year":"2018","unstructured":"Knoll, E. R., Zhu, Z. I., Sarkar, D., Landsman, D. & Morse, R. H. Role of the pre-initiation complex in Mediator recruitment and dynamics. Elife https:\/\/doi.org\/10.7554\/eLife.39633 (2018).","journal-title":"Elife"},{"key":"26860_CR47","doi-asserted-by":"publisher","first-page":"26739","DOI":"10.1073\/pnas.2010885117","volume":"117","author":"S Peissert","year":"2020","unstructured":"Peissert, S., Schlosser, A., Kendel, R., Kuper, J. & Kisker, C. Structural basis for CDK7 activation by MAT1 and Cyclin H. Proc. Natl. Acad. Sci. U. S. A. 117, 26739\u201326748. https:\/\/doi.org\/10.1073\/pnas.2010885117 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"26860_CR48","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1128\/mcb.00637-09","volume":"29","author":"K Glover-Cutter","year":"2009","unstructured":"Glover-Cutter, K. et al. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol. Cell. Biol. 29, 5455\u20135464. https:\/\/doi.org\/10.1128\/mcb.00637-09 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"26860_CR49","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1128\/mcb.00182-12","volume":"32","author":"Z Luo","year":"2012","unstructured":"Luo, Z. et al. The super elongation complex family of RNA polymerase II elongation factors: Gene target specificity and transcriptional output. Mol. Cell. Biol. 32, 2608\u20132617. https:\/\/doi.org\/10.1128\/mcb.00182-12 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"26860_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/21541264.2018.1523668","volume":"10","author":"CW Bacon","year":"2019","unstructured":"Bacon, C. W. & D\u2019Orso, I. CDK9: A signaling hub for transcriptional control. Transcription 10, 57\u201375. https:\/\/doi.org\/10.1080\/21541264.2018.1523668 (2019).","journal-title":"Transcription"},{"key":"26860_CR51","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.18632\/oncotarget.27334","volume":"10","author":"TM Decker","year":"2019","unstructured":"Decker, T. M. et al. Analog-sensitive cell line identifies cellular substrates of CDK9. Oncotarget 10, 6934\u20136943. https:\/\/doi.org\/10.18632\/oncotarget.27334 (2019).","journal-title":"Oncotarget"},{"key":"26860_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ajhg.2018.12.013","volume":"104","author":"C Coutton","year":"2019","unstructured":"Coutton, C. et al. Bi-allelic mutations in ARMC2 lead to severe astheno-teratozoospermia due to sperm flagellum malformations in humans and mice. Am. J. Hum. Genet. 104, 331\u2013340. https:\/\/doi.org\/10.1016\/j.ajhg.2018.12.013 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"26860_CR53","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/j.1365-2443.2011.01565.x","volume":"16","author":"T Tsutsui","year":"2011","unstructured":"Tsutsui, T., Fukasawa, R., Tanaka, A., Hirose, Y. & Ohkuma, Y. Identification of target genes for the CDK subunits of the Mediator complex. Genes Cells 16, 1208\u20131218. https:\/\/doi.org\/10.1111\/j.1365-2443.2011.01565.x (2011).","journal-title":"Genes Cells"},{"key":"26860_CR54","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1073\/pnas.0610856104","volume":"104","author":"WC Zimmerman","year":"2007","unstructured":"Zimmerman, W. C. & Erikson, R. L. Polo-like kinase 3 is required for entry into S phase. Proc. Natl. Acad. Sci. U.S.A. 104, 1847\u20131852. https:\/\/doi.org\/10.1073\/pnas.0610856104 (2007).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"26860_CR55","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.4161\/cc.3.12.1277","volume":"3","author":"F Burrows","year":"2004","unstructured":"Burrows, F., Zhang, H. & Kamal, A. Hsp90 activation and cell cycle regulation. Cell Cycle (Georgetown, Tex.) 3, 1530\u20131536. https:\/\/doi.org\/10.4161\/cc.3.12.1277 (2004).","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"key":"26860_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2741\/s303","volume":"4","author":"E Telles","year":"2012","unstructured":"Telles, E. & Seto, E. Modulation of cell cycle regulators by HDACs. Front. Biosci. (Schol Ed.) 4, 831\u2013839. https:\/\/doi.org\/10.2741\/s303 (2012).","journal-title":"Front. Biosci. (Schol Ed.)"},{"key":"26860_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052","author":"P Wee","year":"2017","unstructured":"Wee, P. & Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers https:\/\/doi.org\/10.3390\/cancers9050052 (2017).","journal-title":"Cancers"},{"key":"26860_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2022.06.002","author":"JM Povedano","year":"2022","unstructured":"Povedano, J. M. et al. TK216 targets microtubules in Ewing sarcoma cells. Cell. Chem. Biol. https:\/\/doi.org\/10.1016\/j.chembiol.2022.06.002 (2022).","journal-title":"Cell. Chem. Biol."},{"key":"26860_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12565-014-0259-5","volume":"90","author":"S Niwa","year":"2015","unstructured":"Niwa, S. Kinesin superfamily proteins and the regulation of microtubule dynamics in morphogenesis. Anat. Sci. Int. 90, 1\u20136. https:\/\/doi.org\/10.1007\/s12565-014-0259-5 (2015).","journal-title":"Anat. Sci. Int."},{"key":"26860_CR60","first-page":"4127","volume":"11","author":"A Ram\u00edrez-Cosmes","year":"2021","unstructured":"Ram\u00edrez-Cosmes, A. et al. The implications of ABCC3 in cancer drug resistance: Can we use it as a therapeutic target?. Am. J. Cancer. Res. 11, 4127\u20134140 (2021).","journal-title":"Am. J. Cancer. Res."},{"key":"26860_CR61","doi-asserted-by":"publisher","first-page":"59476","DOI":"10.18632\/oncotarget.19761","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8, 59476\u201359491. https:\/\/doi.org\/10.18632\/oncotarget.19761 (2017).","journal-title":"Oncotarget"},{"key":"26860_CR62","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/emboj.2012.94","volume":"31","author":"M Ganuza","year":"2012","unstructured":"Ganuza, M. et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J. 31, 2498\u20132510. https:\/\/doi.org\/10.1038\/emboj.2012.94 (2012).","journal-title":"EMBO J."},{"key":"26860_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccell.2019.11.003","volume":"37","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell 37, 37-54.e39. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.003 (2020).","journal-title":"Cancer Cell"},{"key":"26860_CR64","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.chembiol.2019.02.012","volume":"26","author":"CM Olson","year":"2019","unstructured":"Olson, C. M. et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem. Biol. 26, 792-803.e710. https:\/\/doi.org\/10.1016\/j.chembiol.2019.02.012 (2019).","journal-title":"Cell Chem. Biol."},{"key":"26860_CR65","doi-asserted-by":"publisher","first-page":"109394","DOI":"10.1016\/j.celrep.2021.109394","volume":"36","author":"SM Dieter","year":"2021","unstructured":"Dieter, S. M. et al. Degradation of CCNK\/CDK12 is a druggable vulnerability of colorectal cancer. Cell Rep. 36, 109394. https:\/\/doi.org\/10.1016\/j.celrep.2021.109394 (2021).","journal-title":"Cell Rep."},{"key":"26860_CR66","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.59994","author":"L Lv","year":"2020","unstructured":"Lv, L. et al. Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. Elife https:\/\/doi.org\/10.7554\/eLife.59994 (2020).","journal-title":"Elife"},{"key":"26860_CR67","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41467-021-21687-2","volume":"12","author":"Z Andrysik","year":"2021","unstructured":"Andrysik, Z., Bender, H., Galbraith, M. D. & Espinosa, J. M. Multi-omics analysis reveals contextual tumor suppressive and oncogenic gene modules within the acute hypoxic response. Nat. Commun. 12, 1375. https:\/\/doi.org\/10.1038\/s41467-021-21687-2 (2021).","journal-title":"Nat. Commun."},{"key":"26860_CR68","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"26860_CR69","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cell Syst."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26860-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26860-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26860-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T20:14:50Z","timestamp":1672517690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26860-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["26860"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26860-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22505"}}